RESUMO
BACKGROUND: The illicit use and abuse of gamma-hydroxybutyric acid (GHB) occurs due to its sedative/hypnotic and euphoric effects. Currently, there are no clinically available therapies to treat GHB overdose, and care focuses on symptom treatment until the drug is eliminated from the body. Proton- and sodium-dependent monocarboxylate transporters (MCTs (SLC16A) and SMCTs (SLC5A)) transport and mediate the renal clearance and distribution of GHB. Previously, it has been shown that MCT expression is regulated by sex hormones in the liver, skeletal muscle and Sertoli cells. The focus of the current study is to evaluate GHB toxicokinetics and renal monocarboxylate transporter expression over the estrus cycle in females, and in the absence of male and female sex hormones. METHODS: GHB toxicokinetics and renal transporter expression of MCT1, SMCT1 and CD147 were evaluated in females over the estrus cycle, and in ovariectomized (OVX) female, male and castrated (CST) male rats. GHB was administered iv bolus (600 and 1000 mg/kg) and plasma and urine samples were collected for six hours post-dose. GHB concentrations were quantified using a validated LC/MS/MS assay. Transporter mRNA and protein expression was quantified by qPCR and Western Blot. RESULTS: GHB renal clearance and AUC varied between sexes and over the estrus cycle in females with higher renal clearance and a lower AUC in proestrus females as compared to males (intact and CST), and OVX females. We demonstrated that renal MCT1 membrane expression varies over the estrus cycle, with the lowest expression observed in proestrus females, which is consistent with the observed changes in GHB renal clearance. CONCLUSIONS: Our results suggest that females may be less susceptible to GHB-induced toxicity due to decreased exposure resulting from increased renal clearance, as a result of decreased renal MCT1 expression.
Assuntos
Oxibato de Sódio , Ratos , Masculino , Feminino , Animais , Oxibato de Sódio/toxicidade , Oxibato de Sódio/farmacocinética , Ratos Sprague-Dawley , Toxicocinética , Espectrometria de Massas em Tandem , Transportadores de Ácidos Monocarboxílicos/genética , Transportadores de Ácidos Monocarboxílicos/metabolismo , Hormônios Esteroides GonadaisRESUMO
γ-hydroxybutyrate (GHB) is synthesized endogenously from γ-aminobutyric acid (GABA) or exogenously from 1,4-butanediol (butane-1,4-diol; 1,4-BD) or γ-butyrolactone (GBL). GBL, and 1,4-BD are rapidly converted to GHB. The gastric absorption time, volume of distribution, and half-life of GHB are between 5 and 45 min, 0.49 ± 0.9 L/kg, and between 20 and 60 min, respectively. GHB and its analogues have a dose-dependent effect on the activation of GHB receptor, GABA-B, and GABA localized to the central nervous system. After ingestion, most patients present transient neurological disorders (lethal dose: 60 mg/kg). Chronic GHB consumption is associated with disorders of use and a withdrawal syndrome when the consumption is discontinued. GHB, GBL, and 1,4-BD are classified as narcotics but only the use of GHB is controlled internationally. They are used for drug facilitated (sexual) assault, recreational purposes, slamsex, and chemsex. To confirm an exogenous intake or administration of GHB, GBL, or 1-4-BD, the pre-analytical conservation is crucial. The antemortem cutoff doses for detection are 5 and 5-15 mg/L, with detection windows of 6 and 10 h in the blood and urine, respectively Control of GHB is essential to limit the number of users, abuse, associated risks, and death related to their consumption.
Assuntos
Oxibato de Sódio , Síndrome de Abstinência a Substâncias , Humanos , Oxibato de Sódio/toxicidade , 4-Butirolactona/toxicidade , Ácido gama-AminobutíricoRESUMO
N-methyl-2-pyrrolidone (NMP) and γ-hydroxybutyrate acid (GHB) are synthetic solvents detected in the recreational drug market. GHB has sedative/hypnotic properties and is used for criminal purposes to compromise reaction ability and commit drug-facilitated sexual assaults and other crimes. NMP is a strong solubilizing solvent that has been used alone or mixed with GHB in case of abuse and robberies. The aim of this experimental study is to compare the acute pharmaco-toxicological effects of NMP and GHB on neurological signs (myoclonia, convulsions), sensorimotor (visual, acoustic, and overall tactile) responses, righting reflex, thermoregulation, and motor activity (bar, drag, and accelerod test) in CD-1 male mice. Moreover, since cardiorespiratory depression is one of the main adverse effects related to GHB intake, we investigated the effect of NMP and GHB on cardiorespiratory changes (heart rate, breath rate, oxygen saturation, and pulse distension) in mice. The present study demonstrates that NMP inhibited sensorimotor and motor responses and induced cardiorespiratory depression, with a lower potency and efficacy compared to GHB. These results suggest that NMP can hardly be used alone as a substance to perpetrate sexual assault or robberies.
Assuntos
Drogas Ilícitas/toxicidade , Locomoção/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Pirrolidinonas/toxicidade , Reflexo de Sobressalto/efeitos dos fármacos , Oxibato de Sódio/toxicidade , Adjuvantes Anestésicos/toxicidade , Animais , Relação Dose-Resposta a Droga , Hipnóticos e Sedativos/toxicidade , Locomoção/fisiologia , Masculino , Camundongos , Camundongos Endogâmicos ICR , Modelos Animais , Desempenho Psicomotor/fisiologia , Estupro , Reflexo de Sobressalto/fisiologia , Insuficiência Respiratória/induzido quimicamente , Insuficiência Respiratória/fisiopatologiaRESUMO
Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid present endogenously in the brain and used therapeutically for the treatment of narcolepsy, as sodium oxybate, and for alcohol abuse/withdrawal. GHB is better known however as a drug of abuse and is commonly referred to as the "date-rape drug"; current use in popular culture includes recreational "chemsex," due to its properties of euphoria, loss of inhibition, amnesia, and drowsiness. Due to the steep concentration-effect curve for GHB, overdoses occur commonly and symptoms include sedation, respiratory depression, coma, and death. GHB binds to both GHB and GABAB receptors in the brain, with pharmacological/toxicological effects mainly due to GABAB agonist effects. The pharmacokinetics of GHB are complex and include nonlinear absorption, metabolism, tissue uptake, and renal elimination processes. GHB is a substrate for monocarboxylate transporters, including both sodium-dependent transporters (SMCT1, 2; SLC5A8; SLC5A12) and proton-dependent transporters (MCT1-4; SLC16A1, 7, 8, and 3), which represent significant determinants of absorption, renal reabsorption, and brain and tissue uptake. This review will provide current information of the pharmacology, therapeutic effects, and pharmacokinetics/pharmacodynamics of GHB, as well as therapeutic strategies for the treatment of overdoses. Graphical abstract.
Assuntos
Overdose de Drogas/terapia , Hidroxibutiratos/farmacocinética , Oxibato de Sódio/farmacocinética , Abuso Oral de Substâncias/terapia , Alcoolismo/complicações , Alcoolismo/tratamento farmacológico , Animais , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Overdose de Drogas/etiologia , Humanos , Hidroxibutiratos/administração & dosagem , Hidroxibutiratos/toxicidade , Taxa de Depuração Metabólica , Narcolepsia/tratamento farmacológico , Oxibato de Sódio/administração & dosagem , Oxibato de Sódio/toxicidade , Abuso Oral de Substâncias/etiologia , Síndrome de Abstinência a Substâncias/tratamento farmacológicoRESUMO
Introduction: Gamma hydroxybutyrate (GHB) has gained substantial popularity as an illicit recreational drug. The current study aimed to: (1) determine the characteristics and circumstances of death of all recorded cases of GHB-related death in Australia, 2001-2019; (2) determine the toxicology of cases; and (3) determine major organ pathology.Methods: Retrospective study of all Australian cases in which GHB was a mechanism contributory to death retrieved from the National Coronial Information System (n = 74). Information was collected on cause of death, demographics, circumstances of death, toxicology and major organ pathology.Results: The mean age was 31.5 years and 70.3% were male. The predominant circumstance of death was accidental drug toxicity (79.7%), including five cases attributed to a combination of toxicity and natural disease. Other deaths were due to trauma (12.2%) and suicide (8.2%). The fatal incident overwhelmingly occurred in a home environment (82.4%). In all cases, GHB was consumed orally. The median GHB blood concentration was 210 mg/L (range 13-1350 mg/L), and was significantly higher in toxicity cases than others (258 vs. 98 mg/L, p < .01). Other substances were present in 92.2%, most commonly psychostimulants (64.1%), hypnosedatives (28.2%) and alcohol (20.3%). Resuscitation was attempted in 20.3% of cases. Acute pneumonia (36.7%) and aspiration of vomitus (30.6%) were common.Conclusions: The typical case was a young male, who swallowed GHB and used it with other substances, most commonly at home. While acute drug toxicity was the most common cause of death, there was a substantial minority due to trauma or suicide.
Assuntos
Oxibato de Sódio/toxicidade , Adolescente , Adulto , Idoso , Causas de Morte , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Oxibato de Sódio/sangue , Adulto JovemAssuntos
Fármacos do Sistema Nervoso Central/administração & dosagem , Oxibato de Sódio/administração & dosagem , Alcoolismo/tratamento farmacológico , Animais , Fármacos do Sistema Nervoso Central/farmacocinética , Fármacos do Sistema Nervoso Central/toxicidade , Humanos , Drogas Ilícitas/toxicidade , Narcolepsia/tratamento farmacológico , Oxibato de Sódio/farmacocinética , Oxibato de Sódio/toxicidade , ToxicologiaRESUMO
PURPOSE: Gamma-hydroxybutyrate (GHB) withdrawal is a life-threatening condition that does not always respond to standard treatment with benzodiazepines. Baclofen has potential utility as a pharmacological adjunct and anecdotal reports suggest that it is being used by drug users to self-manage GHB withdrawal symptoms. Here, we investigate current patterns of use and the online availably of baclofen. METHODS: Data triangulation techniques were applied to published scientific literature and publicly accessible Internet resources (grey literature) to assess the use of baclofen in GHB withdrawal. An Internet snapshot survey was performed to identify the availability of baclofen for online purchase and the compliance of retailers with the UK regulations. Data were collected according to pre-defined criteria. RESULTS: A total of 37 cases of baclofen use in GHB withdrawal were identified in the scientific literature, as well as 51 relevant discussion threads across eight Internet forums in the grey literature. Baclofen was available to purchase from 38 online pharmacies, of which only one conformed to the UK regulations. CONCLUSIONS: There is limited published evidence on the use of baclofen in GHB withdrawal, but both scientific and grey literature suggests clinical utility. Online pharmacies are readily offering prescription-only-medication without prescription and due to inadequate regulation, pose a danger to the public.
Assuntos
Baclofeno/uso terapêutico , Agonistas dos Receptores de GABA-B/uso terapêutico , Internet , Padrões de Prática Médica , Psicotrópicos/toxicidade , Oxibato de Sódio/toxicidade , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Animais , Baclofeno/economia , Baclofeno/normas , Baclofeno/provisão & distribuição , Pesquisa Biomédica/métodos , Tráfico de Drogas/economia , Agonistas dos Receptores de GABA-B/economia , Agonistas dos Receptores de GABA-B/normas , Agonistas dos Receptores de GABA-B/provisão & distribuição , Humanos , Internet/economia , Internet/ética , Disponibilidade de Medicamentos Via Internet/economia , Disponibilidade de Medicamentos Via Internet/ética , Disponibilidade de Medicamentos Via Internet/normas , Medicamentos sob Prescrição/economia , Medicamentos sob Prescrição/normas , Medicamentos sob Prescrição/provisão & distribuição , Medicamentos sob Prescrição/uso terapêutico , Mídias Sociais/economia , Mídias Sociais/ética , Reino UnidoRESUMO
BACKGROUND: Misuse of gammahydroxybutrate (GHB) and its prodrugs gammabutyrolactone (GBL) and 1,4 butanediol (1,4-BD) has increased greatly since the early 1990s, particularly amongst lesbian, gay, bisexual and transgender (LGBT) individuals in recreational and sexual settings, e.g. 'chemsex'. OBJECTIVE AND METHOD: This paper presents an overview of GHB pharmacotoxicology and provides analyses of cases in the LGBT population associated with the use of these substances extracted from the UK's National Programme on Substance Abuse Deaths database, to which notification is voluntary. RESULTS: From 1995 to September 2013, 21 GHB/GBL-associated fatalities were reported. None involved 1,4-BD. Typical victims were: Male (100%); White (67%), young (mean age 34 years); employed (90%); with a drug misuse history (81%). Most deaths were accidental (67%) or related to recreational drug use (19%), the remaining (potential) suicides. The majority of fatalities (83%) occurred in private residences, typically following recreational use; others occurred in specific 'gay'-oriented locales including clubs and saunas. Three London boroughs accounted for 62% of all notified deaths, reflecting the concentration of both resident and visiting 'gay' individuals. However, this may be an artefact of the voluntary nature of the data submission procedure in particular areas. GHB/GBL alone was implicated in 10% of fatalities. The following substances were implicated either alone or in combination in the remaining cases (percentages may add to more than 100%): cocaine (38%); alcohol (33%); amphetamines (29%); ecstasy (29%); diazepam (24%); ketamine (24%); mephedrone (24%). Post-mortem blood levels: mean 660 (range 22 - 2335; S.D. 726) mg/L. CONCLUSION: Significant caution is needed when ingesting GHB/GBL, particularly with alcohol, benzodiazepines, stimulants, and ketamine. Risk of death is increased due to their CNS-depressant properties. Of these, 'chemsex' drugs such as cocaine, mephedrone and ketamine are of note. More awareness is needed in the 'gay' community about risks associated with the consumption of such substances.
Assuntos
4-Butirolactona/toxicidade , Drogas Ilícitas/toxicidade , Pró-Fármacos/toxicidade , Minorias Sexuais e de Gênero/estatística & dados numéricos , Oxibato de Sódio/toxicidade , 4-Butirolactona/farmacocinética , Morte , Humanos , Drogas Ilícitas/farmacocinética , Pró-Fármacos/farmacocinética , Oxibato de Sódio/farmacocinética , Reino UnidoRESUMO
OBJECTIVE: x03B3;-Hydroxybutyrate (GHB) has gained popularity as a drug of abuse. In the Netherlands the number of patients in treatment for GHB dependence has increased sharply. Clinical presentation of GHB withdrawal can be life threatening. We aim, through this overview, to explore the neurobiological pathways causing GHB dependency and withdrawal, and their implications for treatment choices. METHODS: In this work we review the literature discussing the findings from animal models to clinical studies focused on the neurobiological pathways of endogenous but mainly exogenous GHB. RESULTS: Chronic abuse of GHB exerts multifarious neurotransmitter and neuromodulator effects on x03B3;-aminobutyric acid (GABA), glutamate, dopamine, serotonin, norepinephrine and cholinergic systems. Moreover, important effects on neurosteroidogenesis and oxytocin release are wielded. GHB acts mainly via a bidirectional effect on GABAB receptors (GABABR; subunits GABAB1 and GABAB2), depending on the subunit of the GIRK (G-protein-dependent ion inwardly rectifying potassium) channel involved, and an indirect effect of the cortical and limbic inputs outside the nucleus accumbens. GHB also activates a specific GHB receptor and ß1-subunits of α4-GABAAR. Reversing this complex interaction of neurobiological mechanisms by the abrupt cessation of GHB use results in a withdrawal syndrome with a diversity of symptoms of different intensity, depending on the pattern of GHB abuse. CONCLUSION: The GHB withdrawal symptoms cannot be related to a single mechanism or neurological pathway, which implies that different medication combinations are needed for treatment. A single drug class, such as benzodiazepines, gabapentin or antipsychotics, is unlikely to be sufficient to avoid life-threatening complications. Detoxification by means of titration and tapering of pharmaceutical GHB can be considered as a promising treatment that could make polypharmacy redundant.
Assuntos
Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Oxibato de Sódio/toxicidade , Síndrome de Abstinência a Substâncias/metabolismo , Transtornos Relacionados ao Uso de Substâncias/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Humanos , Oxibato de Sódio/metabolismo , Oxibato de Sódio/farmacologia , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológicoRESUMO
BACKGROUND: Many patients present to emergency departments (EDs) with an altered state of consciousness. Fast exclusion of gamma hydroxybutyrate (GHB)-associated intoxication in these patients may optimize diagnostic and therapeutic algorithms and decisions in the ED. METHODS: Between January and March 2014, a novel enzymatic test system was used to quantify GHB in blood and urine samples of suspected intoxicated patients in the ED of the University Hospital. The underlying causes for suspected intoxication and the diagnostic and therapeutic measures were documented and analysed retrospectively. RESULTS: GHB measurements were performed in 13 patients with suspected ingestion during a 3-month study period. GHB was positive in six patients showing serum levels between 61.8 mg/l and 254.8 mg/l, and GHB was tested negative in seven patients with a range of 0.3-6.2 mg/l (upper reference limit 6.1 mg/l). Additional intoxication was found in five of six GHB positive (83%, alcohol n = 2 and other drugs n = 5) and in six of seven negative-tested patients (86%, alcohol n = 5 and other drugs n = 1). CONCLUSION: GHB quantification in the ED provides specific additional information for intoxication, which can lead to more precise diagnostic and therapeutic decisions and may also be important for legal aspects. We believe that GHB analysis in unconscious patients with suspected intoxication may improve the efficient treatment of intoxicated patients.
Assuntos
Overdose de Drogas , Drogas Ilícitas/sangue , Drogas Ilícitas/urina , Oxibato de Sódio/sangue , Oxibato de Sódio/urina , Detecção do Abuso de Substâncias/métodos , Adulto , Tomada de Decisões , Overdose de Drogas/sangue , Overdose de Drogas/urina , Serviço Hospitalar de Emergência/normas , Feminino , Alemanha , Meia-Vida , Humanos , Drogas Ilícitas/toxicidade , Limite de Detecção , Masculino , Estudos Retrospectivos , Oxibato de Sódio/toxicidadeRESUMO
The illicit recreational drug of abuse, γ-hydroxybutyrate (GHB) is a potent central nervous system depressant and is often encountered during forensic investigations of living and deceased persons. The sodium salt of GHB is registered as a therapeutic agent (Xyrem®), approved in some countries for the treatment of narcolepsy-associated cataplexy and (Alcover®) is an adjuvant medication for detoxification and withdrawal in alcoholics. Trace amounts of GHB are produced endogenously (0.5-1.0 mg/L) in various tissues, including the brain, where it functions as both a precursor and a metabolite of the major inhibitory neurotransmitter γ-aminobutyric acid (GABA). Available information indicates that GHB serves as a neurotransmitter or neuromodulator in the GABAergic system, especially via binding to the GABA-B receptor subtype. Although GHB is listed as a controlled substance in many countries abuse still continues, owing to the availability of precursor drugs, γ-butyrolactone (GBL) and 1,4-butanediol (BD), which are not regulated. After ingestion both GBL and BD are rapidly converted into GHB (t½ ~1 min). The Cmax occurs after 20-40 min and GHB is then eliminated from plasma with a half-life of 30-50 min. Only about 1-5% of the dose of GHB is recoverable in urine and the window of detection is relatively short (3-10 h). This calls for expeditious sampling when evidence of drug use and/or abuse is required in forensic casework. The recreational dose of GHB is not easy to estimate and a concentration in plasma of ~100 mg/L produces euphoria and disinhibition, whereas 500 mg/L might cause death from cardiorespiratory depression. Effective antidotes to reverse the sedative and intoxicating effects of GHB do not exist. The poisoned patients require supportive care, vital signs should be monitored and the airways kept clear in case of emesis. After prolonged regular use of GHB tolerance and dependence develop and abrupt cessation of drug use leads to unpleasant withdrawal symptoms. There is no evidence-based protocol available to deal with GHB withdrawal, apart from administering benzodiazepines.
Assuntos
Oxibato de Sódio/farmacologia , Oxibato de Sódio/toxicidade , Síndrome de Abstinência a Substâncias/terapia , Animais , Interações Medicamentosas , Humanos , Oxibato de Sódio/farmacocinética , Síndrome de Abstinência a Substâncias/psicologia , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/terapiaRESUMO
PURPOSE: Monocarboxylate transporter (MCT) inhibition represents a potential treatment strategy for γ-hydroxybutyric acid (GHB) overdose by blocking its renal reabsorption in the kidney. This study further evaluated the effects of a novel, highly potent MCT inhibitor, AR-C155858, on GHB toxicokinetics/toxicodynamics (TK/TD). METHODS: Rats were administered GHB (200, 600 or 1500 mg/kg i.v. or 1500 mg/kg po) with and without AR-C155858. Breathing frequency was continuously monitored using whole-body plethysmography. Plasma and urine samples were collected up to 8 h. The effect of AR-C155858 on GHB brain/plasma partitioning was also assessed. RESULTS: AR-C155858 treatment significantly increased GHB renal and total clearance after intravenous GHB administration at all the GHB doses used in this study. GHB-induced respiratory depression was significantly improved by AR-C155858 as demonstrated by an improvement in the respiratory rate. AR-C155858 treatment also resulted in a significant reduction in brain/plasma partitioning of GHB (0.1 ± 0.03) when compared to GHB alone (0.25 ± 0.02). GHB CLR and CLoral (CL/F) following oral administration were also significantly increased following AR-C155858 treatment (from 1.82 ± 0.63 to 5.74 ± 0.86 and 6.52 ± 0.88 to 10.2 ± 0.75 ml/min/kg, respectively). CONCLUSION: The novel and highly potent MCT inhibitor represents a potential treatment option for GHB overdose.
Assuntos
Antídotos/farmacologia , Overdose de Drogas/tratamento farmacológico , Rim/efeitos dos fármacos , Transportadores de Ácidos Monocarboxílicos/antagonistas & inibidores , Insuficiência Respiratória/tratamento farmacológico , Oxibato de Sódio/toxicidade , Tiofenos/farmacologia , Uracila/análogos & derivados , Administração Intravenosa , Administração Oral , Animais , Encéfalo/metabolismo , Linhagem Celular , Overdose de Drogas/metabolismo , Rim/metabolismo , Masculino , Taxa de Depuração Metabólica , Transportadores de Ácidos Monocarboxílicos/metabolismo , Ratos Sprague-Dawley , Reabsorção Renal/efeitos dos fármacos , Insuficiência Respiratória/induzido quimicamente , Insuficiência Respiratória/metabolismo , Insuficiência Respiratória/fisiopatologia , Taxa Respiratória/efeitos dos fármacos , Oxibato de Sódio/administração & dosagem , Oxibato de Sódio/farmacocinética , Distribuição Tecidual , Uracila/farmacologiaRESUMO
Overdose of γ-hydroxybutyrate (GHB) can result in severe respiratory depression. Monocarboxylate transporter (MCT) inhibitors, including L-lactate, increase GHB clearance and represent a potential treatment for GHB intoxication. GHB can also affect L-lactate clearance, and L-lactate has been reported to affect respiration. In this research, we characterize these toxicokinetic/toxicodynamic interactions between GHB and L-lactate using mechanistic modeling. Plasma, urine, and respiration data were taken from our previous study in which GHB and sodium L-lactate were administered alone and concomitantly in rats. A model incorporating active renal reabsorption for both agents fit GHB and L-lactate toxicokinetic data. The Km for renal reabsorption of GHB (650 µg/mL) was close to its Km for the proton-dependent MCT1 and that for L-lactate (13.5 µg/mL) close to its Km for the sodium-dependent SMCT1. Inhibition of reabsorption by both agents was necessary to model concomitant drug administration. The metabolic Km for L-lactate closely resembled that for MCT-mediated hepatic uptake in vitro, and GHB inhibited this process. L-lactate significantly inhibited respiration at a high dose, and an indirect response model was used to fit these data. GHB toxicodynamics was modeled as a direct effect delayed by nonlinear transport into the brain extracellular fluid, with a Km value of 1,865 µg/mL for brain uptake which is similar to the in vitro Km value determined in rat brain endothelial cells. This model was useful for characterizing multiple MCT-mediated interactions. Incorporation of many parameters that can be determined in vitro may allow for clinical translation of these interactions.
Assuntos
Anestésicos Intravenosos/farmacocinética , Anestésicos Intravenosos/toxicidade , Ácido Láctico/farmacocinética , Ácido Láctico/toxicidade , Transportadores de Ácidos Monocarboxílicos/química , Oxibato de Sódio/farmacocinética , Oxibato de Sódio/toxicidade , Simportadores/química , Animais , Simulação por Computador , Relação Dose-Resposta a Droga , Overdose de Drogas/prevenção & controle , Ácido Láctico/metabolismo , Masculino , Ratos , Ratos Sprague-Dawley , Mecânica Respiratória/efeitos dos fármacos , ToxicocinéticaRESUMO
Club drugs have become increasingly popular with young adults and adolescents. Although users report similar effects of these drugs, they are pharmacologically and physiologically different. Understanding these differences and recognizing trends and effects of club drugs is essential for nurse practitioners.
Assuntos
Drogas Ilícitas/farmacologia , Drogas Ilícitas/toxicidade , Profissionais de Enfermagem , Enfermagem de Atenção Primária , Transtornos Relacionados ao Uso de Substâncias/enfermagem , Adolescente , Adulto , Feminino , Flunitrazepam/farmacologia , Flunitrazepam/toxicidade , Humanos , Ketamina/farmacologia , Ketamina/toxicidade , Dietilamida do Ácido Lisérgico/farmacologia , Dietilamida do Ácido Lisérgico/toxicidade , Metanfetamina/farmacologia , Metanfetamina/toxicidade , N-Metil-3,4-Metilenodioxianfetamina/farmacologia , N-Metil-3,4-Metilenodioxianfetamina/toxicidade , Oxibato de Sódio/farmacologia , Oxibato de Sódio/toxicidade , Adulto JovemRESUMO
γ-Hydroxybutyrate (GHB), a common drug of abuse, is often coingested with ethanol. Increasing renal clearance via monocarboxylate transporter (MCT) inhibition represents a potential therapeutic strategy in GHB overdose, as does inhibition of GABAB receptors. In this study, we investigate toxicokinetic/toxicodynamic interactions between GHB-ethanol and efficacy of treatment options for GHB-ethanol intoxication in rats. Sedation was assessed using the endpoint of return-to-righting reflex. Respiration was assessed using plethysmography. Coadministration of 2.0 g/kg ethanol i.v. with 600 mg/kg GHB i.v. increased sleep time compared with GHB alone. Administration of ethanol to steady-state concentrations of 0.1-0.2% and 0.3-0.4% (w/v) did not affect toxicokinetics of 600 mg/kg GHB i.v., or respiratory rate, but did result in significantly lower peak tidal volumes compared with GHB alone. Oral administration of 2.5 g/kg ethanol had no significant effect on toxicokinetics of 1500 mg/kg orally administered GHB. Pretreatment with specific receptor inhibitors indicated no effect of GABAA receptor inhibition on sleep time or respiratory depression in GHB-ethanol intoxication. GABAB receptor inhibition partially prevented sedation and completely prevented respiratory depression. Ethanol increased fatality when administered at 0.1-0.2% (4 of 10) and 0.3-0.4% (9 of 10) versus 1500 mg/kg GHB i.v. alone (0 of 10). Treatment with the MCT inhibitor, l-lactate, significantly decreased sleep time after GHB-ethanol and decreased fatality at 0.1-0.2% (0 of 10) and 0.3-0.4% ethanol (5 of 10). Treatment with a GABAB receptor antagonist completely prevented fatality at 0.3-0.4% (0 of 10). These data indicate that ethanol potentiates the sedative and respiratory depressant effects of GHB, increasing the risk of fatality. MCT and GABAB receptor inhibition represent potentially effective treatments in GHB-ethanol intoxication.
Assuntos
Depressores do Sistema Nervoso Central/farmacocinética , Depressores do Sistema Nervoso Central/toxicidade , Etanol/farmacocinética , Etanol/toxicidade , Hipnóticos e Sedativos/farmacocinética , Hipnóticos e Sedativos/toxicidade , Intoxicação/tratamento farmacológico , Oxibato de Sódio/farmacocinética , Oxibato de Sódio/toxicidade , Animais , Sedação Consciente/mortalidade , Overdose de Drogas/tratamento farmacológico , Antagonistas de Receptores de GABA-B/farmacologia , Ácido Láctico/uso terapêutico , Masculino , Transportadores de Ácidos Monocarboxílicos/antagonistas & inibidores , Transportadores de Ácidos Monocarboxílicos/metabolismo , Pletismografia , Ratos , Ratos Sprague-Dawley , Insuficiência Respiratória/induzido quimicamente , Insuficiência Respiratória/tratamento farmacológico , Insuficiência Respiratória/mortalidade , Mecânica Respiratória/efeitos dos fármacosRESUMO
Respiratory depression and death secondary to respiratory arrest have occurred after oral overdoses of γ-hydroxybutyrate (GHB) and its precursor γ-butyrolactone (GBL). GHB is a substrate for monocarboxylate transporters (MCTs), and increasing GHB renal clearance or decreasing GHB absorption via MCT inhibition represents a potential treatment strategy for GHB/GBL overdose. In these studies, GHB and GBL were administered in doses of 1.92, 5.77, and 14.4 mmol/kg orally with and without MCT inhibition to determine effects of this treatment strategy on the oral toxicokinetics and toxicodynamics of GHB and GBL. The competitive MCT inhibitor l-lactate was administered by intravenous infusion starting 1 hour after GHB and GBL administration. Oral administration of l-lactate and the MCT inhibitor luteolin was also evaluated. Respiratory depression was measured using plethysmography. Intravenous l-lactate, but not oral treatments, significantly increased GHB renal and/or oral clearances. At the low dose of GHB and GBL, i.v. l-lactate increased GHB renal clearance. Due to the increased contribution of renal clearance to total clearance at the moderate dose, increased renal clearance translated to an increase in oral clearance. At the highest GHB dose, oral clearance was increased without a significant change in renal clearance. The lack of effect of i.v. l-lactate on renal clearance after a high oral GHB dose suggests possible effects of i.v. l-lactate on MCT-mediated absorption. The resulting increases in oral clearance improved respiratory depression. Intravenous l-lactate also reduced mortality with the high GBL dose. These data indicate i.v. l-lactate represents a potential treatment strategy in oral overdose of GHB and GBL.
Assuntos
4-Butirolactona , Overdose de Drogas/tratamento farmacológico , Ácido Láctico/uso terapêutico , Transportadores de Ácidos Monocarboxílicos/antagonistas & inibidores , Insuficiência Respiratória/prevenção & controle , Oxibato de Sódio , 4-Butirolactona/farmacocinética , 4-Butirolactona/toxicidade , Absorção , Administração Oral , Animais , Relação Dose-Resposta a Droga , Overdose de Drogas/etiologia , Overdose de Drogas/metabolismo , Humanos , Injeções Intravenosas , Rim/efeitos dos fármacos , Rim/metabolismo , Ácido Láctico/administração & dosagem , Ácido Láctico/farmacologia , Masculino , Taxa de Depuração Metabólica , Ratos , Ratos Sprague-Dawley , Insuficiência Respiratória/induzido quimicamente , Insuficiência Respiratória/metabolismo , Oxibato de Sódio/farmacocinética , Oxibato de Sódio/toxicidadeRESUMO
PURPOSE: L-lactate represents a potential treatment for GHB overdose by inhibiting GHB renal reabsorption mediated by monocarboxylate transporters. Our objective was to assess the dose-dependence of L-lactate treatment, with and without D-mannitol, on GHB toxicokinetics/toxicodynamics (TK/TD). METHODS: Rats were administered GHB 600 mg/kg i.v. with L-lactate (low and high doses), D-mannitol, or L-lactate (low dose) with D-mannitol. GHB-induced sleep time and GHB plasma, urine and brain extracellular fluid (ECF) concentrations (by LC/MS/MS) were determined. The effect of L-lactate and D-mannitol on the uptake and efflux of GHB was assessed in rat brain endothelial RBE4 cells. RESULTS: L-lactate treatment increased GHB renal clearance from 1.4 ± 0.1 ml/min/kg (control) to 2.4 ± 0.2 and 4.7 ± 0.5 ml/min/kg after low and high doses, respectively, and reduced brain ECF AUC values to 65 and 25% of control. Sleep time was decreased from 137 ± 12 min (control) to 91 ± 16 and 55 ± 5 min (low and high L-lactate, respectively). D-mannitol did not alter GHB TK/TD and did not alter L-lactate's effects on GHB TK/TD. L-lactate, but not D-mannitol, inhibited GHB uptake, and increased GHB efflux from RBE4 cells. CONCLUSIONS: L-lactate decreases plasma and brain ECF concentrations of GHB, decreasing sedative/hypnotic effects.
Assuntos
Encéfalo/efeitos dos fármacos , Hipnóticos e Sedativos/toxicidade , Ácido Láctico/uso terapêutico , Sono/efeitos dos fármacos , Oxibato de Sódio/toxicidade , Animais , Encéfalo/metabolismo , Linhagem Celular , Overdose de Drogas , Humanos , Hipnóticos e Sedativos/sangue , Hipnóticos e Sedativos/metabolismo , Hipnóticos e Sedativos/urina , Ácido Láctico/administração & dosagem , Masculino , Manitol/administração & dosagem , Manitol/uso terapêutico , Permeabilidade/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Oxibato de Sódio/sangue , Oxibato de Sódio/metabolismo , Oxibato de Sódio/urinaRESUMO
Gamma-hydroxybutyrate (GHB), and its precursors 1,4-butanediol (1,4-BD) and gamma-butyrolactone (GBL) are known drugs of abuse. The ability of acute and chronic administration of equimolar doses of GHB (200mg/kg), 1,4-BD (174mg/kg) and GBL (166mg/kg) to produce catalepsy in male Swiss Webster mice was examined. GHB, 1,4-BD, GBL produced catalepsy when injected acutely. Drug treatment was then continued for 14days. Tolerance development was determined on days 6, 14, and challenged with a higher dose on day 15 in those chronically pretreated mice, and compared with naïve mice. Chronic GHB produced tolerance to catalepsy, as evidenced from area under the curve (AUC) of catalepsy versus time (min-sec) on days 6 (678±254), 14 (272±247), which were less than those on day 1 (1923±269). However, less tolerance was seen from GBL or 1,4-BD, as AUCs on days 6 and 14 were not significantly lower than that of day 1. In conclusion, although equimolar doses were used, expecting similar levels of GHB in the body, 1,4-BD and GBL shared only some of the in vivo effects of GHB. The rate of metabolic conversion of 1,4-BD and GBL into GHB might be responsible for the differences in the tolerance development to these drugs.
Assuntos
4-Butirolactona/administração & dosagem , Butileno Glicóis/administração & dosagem , Catalepsia/induzido quimicamente , Tolerância a Medicamentos , Oxibato de Sódio/administração & dosagem , 4-Butirolactona/toxicidade , Animais , Área Sob a Curva , Butileno Glicóis/toxicidade , Relação Dose-Resposta a Droga , Masculino , Camundongos , Oxibato de Sódio/toxicidade , Testes de Toxicidade Aguda , Testes de Toxicidade CrônicaRESUMO
CONTEXT: Intoxications with gamma-hydroxybutyrate (GHB) are occurring more frequently. Patients are primarily treated symptomatically. The use of activated charcoal (AC) has been suggested in several guidelines and in literature, although the clinical value of AC in GHB intoxication is a matter of debate. However, it has never been demonstrated that GHB binds to AC. Under certain conditions, prevention of absorption could be clinically relevant. Therefore, adsorption of GHB to AC in an in vitro model was tested. MATERIALS AND METHODS: A previously described in vitro model was used. Dosages of 2.5, 5, 7.5, or 10 g of standard AC (simulating in vivo dosages of approximately 25-100 g) were mixed with a dose of 800 mg GHB at 37 °C in 100 mL simulated gastric or intestinal fluid, respectively. Subsequently, the AC was separated from the liquid by centrifugation and the remaining GHB quantified by gas chromatography. GHB adsorption capacity was plotted in an adsorption curve. RESULTS: Binding of GHB to AC was dose-dependent. At gastric pH, adsorption was higher than at intestinal pH, with a maximum adsorption of 84.3% and 23.3%, respectively, with 10 g of AC, corresponding with a high adult dose. DISCUSSION AND CONCLUSION: AC has clinically relevant GHB binding capacity, which is pH dependent. The normally rapid adsorption and the need for intubation argue against AC treatment in GHB intoxications. However, under certain circumstances e.g. in case of unintentional intake of GHB by children or in case of very high doses of GHB, rapid treatment with AC may still be appropriate. In vivo studies are needed to establish the clinical relevance of GHB adsorption to AC.